
Medical Malpractice Laws in Delaware (2026): Deadlines & Caps
Delaware medical malpractice law: a 2-year deadline (3-year discovery limit) under 18 Del. C. 6856, the 18 Del. C. 6853 affidavit of merit, and no damage caps.
Browse our full library of legal guides, state law breakdowns, and practical legal information.
14746 articles
Browse by Category →
Delaware medical malpractice law: a 2-year deadline (3-year discovery limit) under 18 Del. C. 6856, the 18 Del. C. 6853 affidavit of merit, and no damage caps.

Connecticut medical malpractice law: a 2-year deadline and 3-year repose under Conn. Gen. Stat. 52-584, the 52-190a good-faith certificate, and no damage caps.

Colorado medical malpractice in 2026: the 2-year deadline and 3-year repose (C.R.S. 13-80-102.5), the new HB24-1472 damage caps, and the certificate of review.

California medical malpractice in 2026: the 3-year/1-year deadline (CCP 340.5), the rising MICRA caps ($470,000 injury / $650,000 death), and 90-day notice.

Arkansas medical malpractice in 2026: the strict 2-year deadline (Ark. Code 16-114-203), why the constitution bars damage caps, and the affidavit-of-merit rule.

Arizona medical malpractice law: 2-year deadline with a discovery rule, no damage caps (constitutionally barred), and the expert affidavit rule, explained.

Alaska medical malpractice law: 2-year filing deadline with a discovery rule, 10-year repose, a $250,000 noneconomic cap ($400,000 in death cases), explained.

Alabama medical malpractice law: 2-year filing deadline, 4-year statute of repose, no damage caps (struck down), and the strict AMLA pleading rules, explained.

Plaintiffs allege Cook retrievable IVC blood-clot filters can fracture, migrate, or perforate the vena cava. Federal MDL 2570 and status as of June 2026.

Bard PowerPort lawsuits allege the implanted catheter can fracture or migrate. Covers the fracture allegations, federal MDL 3081, and the first bellwether's defense verdict.

Plaintiffs allege the Paragard copper IUD can break on removal. Federal MDL 2974, the first bellwether defense verdict, and the second trial set for April 2027.

People who took Ozempic, Wegovy, or Rybelsus and developed NAION sudden vision loss allege eye injuries. Federal MDL 3163 explained, status as of September 2026.